Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor
Engineered <i>E. coli</i> hGC33-OMVs effectively target HCC via the hGC33-GPC3 interaction, inhibit tumor growth by suppressing Wnt signaling, and demonstrate potential for use as a versatile platform for antibody delivery.
Authors
- Hanyu Xiao (ORCID: https://orcid.org/0000-0002-7674-0801)
- Jin Bai (ORCID: https://orcid.org/0000-0002-7959-5048)
- Liaoqiong Fang (ORCID: https://orcid.org/0000-0002-3233-8351)
- Yufei Deng (ORCID: https://orcid.org/0009-0008-4671-5104)
- Zelan Yang
- Cheng Zou (ORCID: https://orcid.org/0000-0003-3632-5221)
- Yan Zou
- Xi Sun
- Zhibiao Wang (ORCID: https://orcid.org/0000-0001-8148-2117)
- Yang Song (ORCID: https://orcid.org/0009-0001-4271-4015)
- Yi‐Ting Wang (ORCID: https://orcid.org/0000-0003-2008-4435)
- Bangya Yang
Institutions
- Chongqing Medical University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ijn.s513508
- Citations
- 1
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.23